Simple Summary While KRAS is a driver oncogene, tumor cells can acquire mutant KRAS
independency by activating pathways that functionally substitute for mutant KRAS. These …

Mutations in K irsten rat‐sarcoma (KRAS) are well appreciated to be major drivers of human
cancers through dysregulation of multiple growth and survival pathways. Similar to many …

Combinatorial inhibition of effector and feedback pathways is a promising treatment strategy
for KRAS mutant cancers. However, the particular pathways that should be targeted to …

Simple Summary Since the Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated
in about 25% of all human cancers and is at the center of pathways involved in …

KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been
approved to treat these tumors. Despite the recent development of drugs that block KRAS …

KRAS is the most commonly mutated oncogene in human cancer. Most KRAS-mutant
cancers depend on sustained expression and signaling of KRAS, thus making it a high …

Simple Summary KRAS is one of the oncogenic proteins and best well-known GTPase
proteins. Although KRAS serves as regulation of cellular process, abnormal mutated and …

Cancer remains the leading cause of global mortality, prompting a paradigm shift in its
treatment and outcomes with the advent of targeted therapies. Among the most prevalent …

KRAS is a small GTPase that is among the most commonly mutated oncogenes in cancer.
Here, we discuss KRAS biology, therapeutic avenues to target it, and mechanisms of …

Over the past decades, designing therapeutic strategies to target KRAS-mutant cancers,
which is one of the most frequent mutant oncogenes among all cancer types, have proven …